ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth - Regular Plan

  • Previous Nav

  • Net Change on 25-11-2022

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

To generate long-term capital appreciation by creating a portfolio that is invested in Equity and Equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.However there can be no assurance that the investment objectives of the scheme will be realized.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
S&P BSE Health Care - TRI 0.30 4.04 -5.91 21.08 11.70 13.67

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 -3.99 23.89 15.95 1.94 4,785.53
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 3.32 24.39 12.27 2.12 1,728.21
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 -5.70 21.91 11.82 2.39 725.41
Tata India Pharma & Healthcare Fund-Regular Plan-Growth Dec 28, 2015 -1.18 22.35 14.25 2.50 535.42

Fund Holdings as on 31-October-2022

  • Sun Pharmaceutical Industries Ltd.

  • Dr. Reddy's Laboratories Ltd.

  • Lupin Ltd.

  • Alkem Laboratories Ltd.

  • Aurobindo Pharma Ltd.

  • FDC Ltd.

  • Sanofi India Ltd.

  • Torrent Pharmaceuticals Ltd.

  • Apollo Hospitals Enterprise Ltd.

  • Divi's Laboratories Ltd.

  • Cipla Ltd.

  • Natco Pharma Ltd.

  • Indoco Remedies Ltd.

  • SBI Life Insurance Company Ltd.

  • Biocon Ltd.

  • Fortis Healthcare Ltd.

  • Aster DM Healthcare Ltd.

  • Glaxosmithkline Pharmaceuticals Ltd.

  • TREPS

  • IPCA Laboratories Ltd.

  • Viatris Inc.

  • Krsnaa Diagnostics Ltd.

  • Gland Pharma Ltd.

  • Narayana Hrudayalaya Ltd.

  • Zydus Lifesciences Ltd.

  • ICICI Lombard General Insurance Company Ltd.

  • Syngene International Ltd.

  • Ajanta Pharma Ltd.

  • Windlas Biotech Ltd.

  • J.B.Chemicals & Pharmaceuticals Ltd.

  • Dishman Carbogen Amcis Ltd.

  • Cash Margin - Derivatives

  • Net Current Assets

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Insurance

  • Miscellaneous

View More

Fund Manager

  • Cash

  • Equity

View More

About ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

Scheme Analysis

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ICICI Prudential Mutual Fund. It was launched on 13-Jul-2018 and currently has an AUM of ₹2,598.34 crore. ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is benchmarked against NIFTY 50 - TRI as primary index and S&P BSE Health Care - TRI as secondary index.

The NAV of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund ended up ₹0.09(0.46%)yesterday to ₹19.6.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Ltd., and

The ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund is managed by Priyanka Khandelwal and Dharmesh Kakkad.

Fund House Contact

One BKC, A - Wing 13th Floor, Bandra Kurla Complex, Bandra (East) Mumbai - 400 051

+91 (22) 2652 5000
enquiry@icicipruamc.com
+91 (22) 2652 8100